Outras Publicações

2021

MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era
Kim WR, Mannalithara A, Heimbach JK, et al.
Gastroenterology. 2021 Sep 2:S0016-5085(21)03469-7.
doi: 10.1053/j.gastro.2021.08.050
link

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
Pinato DJ, Kaseb A, Wang Y, et al.
J Immunother Cancer. 2020 Oct;8(2):e000726.
doi: 10.1136/jitc-2020-000726
descarregue aqui o pdf

Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis
Martínez J, Hernández-Gea V, Rodríguez-de-Santiago E, et al.
J Hepatol. 2021 Aug;75(2):342-350.
doi: 10.1016/j.jhep.2021.03.026
descarregue aqui o pdf

Portal pressure measurement: Have we come full circle?
Bazarbashi AN, Ryou M.
Gastrointest Endosc. 2021 Mar;93(3):573-576.
doi: 10.1016/j.gie.2020.08.007. PMID: 33583516
descarregue aqui o pdf

Hepatic Manifestations of Urea Cycle Disorders
Strong, A., Gold, J., Gold, N.B., Yudkoff, M.
Clinical Liver Disease. 2021.
doi: 10.1002/cld.1115
descarregue aqui o pdf

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis
Vuppalanchi R, Caldwell SH, Pyrsopoulos N, et al.
J Hepatol. 2021 Sep 3:S0168-8278(21)02023-7.
doi: 10.1016/j.jhep.2021.08.025
link

Friend or Foe? Spontaneous Portosystemic Shunts in Cirrhosis-Current Understanding and Future Prospects
Rajesh S, Philips CA, Ahamed R, et al.
Gastroenterol Hepatol. 2021 Aug 12;2021:8795115.
doi: 10.1155/2021/8795115
descarregue aqui o pdf

Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic
Kaufman HW, Bull-Otterson L, Meyer WA 3rd, et al.
Am J Prev Med. 2021 Sep;61(3):369-376.
doi: 10.1016/j.amepre.2021.03.011
descarregue aqui o pdf

Mistakes in nutrition in chronic liver disease and how to avoid them
Merli M and Lapenna L.
UEG Education 2021; 21: 23–25.
descarregue aqui o pdf

Hepatic Manifestations of Immunoglobulin G4-Related Disease
Sharzehi, K.
Clinical Liver Disease. 2021.
doi: 10.1002/cld.1087
descarregue aqui o pdf

Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH)
Senussi NH, McCarthy DM.
Ann Hepatol. 2021 Sep-Oct;24:100526.
doi: 10.1016/j.aohep.2021.100526
descarregue aqui o pdf

Liver Biopsy in Patients With Alcohol-Associated Liver Disease With Acute-on-Chronic Liver Failure
Jophlin, Loretta et al.
Journal of Clinical and Experimental Hepatology. 2021.
doi: 10.1016/j.jceh.2021.08.009
descarregue aqui o pdf

Tuberculosis in cirrhosis- A diagnostic and management conundrum
Mishra, Saurabh et al.
Journal of Clinical and Experimental Hepatology. 2021.
doi: 10.1016/j.jceh.2021.09.003
descarregue aqui o pdf

Cholangiocarcinoma
Brindley PJ, Bachini M, Ilyas SI, et al.
Nat Rev Dis Primers. 2021 Sep 9;7(1):65.
doi: 10.1038/s41572-021-00300-2
descarregue aqui o pdf

Wilson’s disease: Revisiting an old friend
Lucena-Valera A, Perez-Palacios D, Muñoz-Hernandez R, et al.
World J Hepatol. 2021 Jun 27;13(6):634-649.
doi: 10.4254/wjh.v13.i6.634
descarregue aqui o pdf

Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice
Ferrarese A, Passigato N, Cusumano C, et al.
World J Hepatol 2021; 13(8): 840-852.
doi: 10.4254/wjh.v13.i8.840
descarregue aqui o pdf

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Greten TF, Abou-Alfa GK, Cheng AL, et al.
J Immunother Cancer. 2021 Sep;9(9):e002794.
doi: 10.1136/jitc-2021-002794
descarregue aqui o pdf

Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis
Juanola A, Graupera I, Elia C, et al.
J Hepatol. 2021 Sep 13:S0168-8278(21)02029-8.
doi: 10.1016/j.jhep.2021.08.031
descarregue aqui o pdf

Non-alcoholic fatty liver disease: A patient guideline
Francque S, Marchesini G, Kautz A, et al.
JHEP Reports. 2021.
doi: 10.1016/j.jhepr.2021.100322
descarregue aqui o pdf

Developing Priorities for Palliative Care Research in Advanced Liver Disease: A Multidisciplinary Approach
Patel AA, Woodrell C, Ufere NN, et al.
Hepatol Commun. 2021 Sep;5(9):1469-1480.
doi: 10.1002/hep4.1743
descarregue aqui o pdf

Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma
Lee YT, Wang JJ, Zhu Y, Agopian VG, Tseng HR, Yang JD.
Clin Liver Dis (Hoboken). 2021 Aug 5;17(6):409-413.
doi: 10.1002/cld.1075
descarregue aqui o pdf

Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study
Mahmud N, Fricker Z, Lewis JD, Taddei TH, Goldberg DS, Kaplan DE.
Clin Gastroenterol Hepatol. 2021 Jul 8:S1542-3565(21)00721-7.
doi: 10.1016/j.cgh.2021.06.050. Epub ahead of print.
link

More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC
Zanetto A., Elena C., Bulato C. et al.
Hepatology Communications. 2021.
doi: 10.1002/hep4.1781
descarregue aqui o pdf

Diagnosis and Management of Cirrhotic Cardiomyopathy
Kaur H., Premkumar M.
J Clin Exp Hepatol. 2021.  ISSN 0973-6883.
doi: 10.1016/j.jceh.2021.08.016
descarregue aqui o pdf

Magnetic resonance elastography for the clinical risk assessment of fibrosis, cirrhosis, and portal hypertension in patients with NAFLD
Natarajan Y., Loomba R.
J Clin Exp Hepatol. 2021 Aug.
Doi: 10.1016/j.jceh.2021.08.002
descarregue aqui o pdf

Appropriate Clinical Genetic Testing of Hemochromatosis Type 2-4, Including Ferroportin Disease
Kowdley DS, Kowdley KV.
Appl Clin Genet. 2021 Aug 12;14:353-361.
doi: 10.2147/TACG.S269622
descarregue aqui o pdf

Viral Hepatitis in Pregnancy: An Update on Screening, Diagnosis, and Management
Sanghi, V. and Lindenmeyer, C.C.
Clinical Liver Disease. 2021. 18: 7-13.
doi: 10.1002/cld.1079
descarregue aqui o pdf

Microbiome Therapeutics for Hepatic Encephalopathy
Bloom P, Tapper EB, Young VB, Lok AS.
J Hepatol. 2021 Aug 25:S0168-8278(21)01998-X.
doi: 10.1016/j.jhep.2021.08.004
descarregue aqui o pdf

Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis
Thomson MJ, Lok ASF, Tapper EB.
Hepatology. 2021 Jun;73(6):2429-2440.
doi: 10.1002/hep.31548
link

Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study
Arab JP, Díaz LA, Baeza N et al.
J Hepatol. 2021 Jun 21:S0168-8278(21)00439-6.
doi: 10.1016/j.jhep.2021.06.019
descarregue aqui o pdf

History of Hepatic Encephalopathy is Not a Contraindication to TIPS Placement for Refractory Ascites
Saab S, Zhao M, Asokan I, Yum JJ, Lee EW.
SSRN Electron J. Published online 2020:1-9.
doi:10.2139/ssrn.3702918
descarregue aqui o pdf

When and how to use direct oral anticoagulants in patients with advanced chronic liver disease?
Maria C De, Galante A, Fasoli A, Gottardi A De.
ScienceDirect Pharmacology Curr Opin Pharmacol. 2021;60:111-116.
doi:10.1016/j.coph.2021.07.006
link

COVID‐19 ‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality
Hartl L, Semmler G, Hofer BS, et al.
Hepatol Commun. 2021;0(0):1-16.
doi:10.1002/hep4.1758
descarregue aqui o pdf

Liver biopsy in patients with alcohol-associated liver disease with acute on chronicliver failure
Jophlin L, Singal A.K.
Journal of Clinical and Experimental Hepatology. 2021, ISSN 0973-6883.
doi:10.1016/j.jceh.2021.08.009
descarregue aqui o pdf

Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis
Laschtowitz A, Zachou K, Lygoura V, et al.
JHEP Reports. 2021;3(4):100321.
doi:10.1016/j.jhepr.2021.100321
descarregue aqui o pdf

Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis
Ratziu V.
Clin Liver Dis. 2021;17(6):398-400.
doi:10.1002/cld.1076
descarregue aqui o pdf

Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis
Koh JH, Liew ZH, Ng GK, et al.
Dig Liver Dis. 2021.
doi:10.1016/j.dld.2021.07.039
descarregue aqui o pdf

Decreasing VWF-levels upon NSBB-therapy indicate a decreased risk of further decompensation, ACLF, and death
Jachs M, Hartl L, Simbrunner B, et al.
Clin Gastroenterol Hepatol. 2021;(August).
doi:10.1016/j.cgh.2021.07.012
descarregue aqui o pdf

Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors
Turon F, Driever EG, Baiges A, et al.
J Hepatol. Published online 2021.
doi:10.1016/j.jhep.2021.07.020
link

Poor Awareness of Liver Disease Among Adults With NAFLD in the United States
Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM.
Hepatol Commun. 2021;0(0):1-3.
doi:10.1002/hep4.1765
descarregue aqui o pdf

NAFLD Cirrhosis Is Rising Among Childbearing Women and Is the Most Common Cause of Cirrhosis in Pregnancy
Sarkar M, Djerboua M, Flemming JA.
Clin Gastroenterol Hepatol. Published online 2021.
doi:10.1016/j.cgh.2021.01.022
Link

2021 ISHEN guidelines on animal models of hepatic encephalopathy
DeMorrow S, Cudalbu C, Davies N, Jayakumar AR, Rose CF.
Liver Int. 2021;41(7):1474-1488.
doi:10.1111/liv.14911
descarregue aqui o pdf

Imaging biomarkers of NAFLD, NASH, and fibrosis
Ajmera V, Loomba R.
Mol Metab. 2021;50(January):1-7.
doi:10.1016/j.molmet.2021.101167
descarregue aqui o pdf

Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study)
Engelmann C, Herber A, Franke A, et al.
J Hepatol. Published online 2021.
doi:10.1016/j.jhep.2021.07.033
Link

Down-staging Outcomes for Hepatocellular Carcinoma: Results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium
Mehta, N., Frenette, C., Tabrizian, P., et al.
Gastroenterology. 2021;0(0).
doi:10.1053/J.GASTRO.2021.07.033
Link

Evaluation of Early vs Standard Liver Transplant for Alcohol-Associated Liver Disease
Herrick-Reynolds, K. M., Punchhi, G., Greenberg, R. S., et al.
JAMA Surg. Published online August 11, 2021.
doi:10.1001/JAMASURG.2021.3748
Link

Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study
Rumgay H, Shield K, Hadrien Charvat, et al.
Lancet Oncol. 2021 Jul 13:S1470-2045(21)00279-5.
doi:10.1016/S1470-2045(21)00279-5
descarregue aqui o pdf

Changes in ascitic fluid polymorphonuclear cell counts impact mortality in patients with spontaneous bacterial peritonites
Santana E, Rezende V, Lima GC, et al.
Clin Gastroenterol Hepatol. 2021 Jul 14:S1542-3565(21)00750-3.
doi: 10.1016/j.cgh.2021.07.019
descarregue aqui o pdf

Systemic treatment of hepatocellular carcinoma. An EASL position paper
Bruix J, Chan SL, Galle PR, et al.
J Hepatol. 2021 Jul 10:S0168-8278(21)01903-6.
doi:10.1016/j.jhep.2021.07.004
descarregue aqui o pdf

Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management
Mehta N.
Clin Liver Dis. 2021;17(5):332-336.
doi:10.1002/cld.1054
descarregue aqui o pdf

Liver abscess: Complications and Treatment
Sharma S, Ahuja V.
Clinical Liver Disease 2021;0(0):1-5.
doi:10.1002/cld.1128
descarregue aqui o pdf

North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension
Zhou H, Chen R, Wang J, et al.
Clin Gastroenterol Hepatol. 2021 Jul 15:S1542-3565(21)00749-7.
doi:10.1016/j.cgh.2021.07.018
descarregue aqui o pdf

Maternal obesity increases the risk and severity of NAFLD in offspring
Hannes Sharma HB, Panigrahi S, Sarmah AK, Dubey BK.
J Hepatol. 2021 Jul 10:S0168-8278(21)01899-7.
doi:10.1016/j.jhep.2021.06.045
descarregue aqui o pdf

Safety , Efficacy , and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma : Randomized Expansion of a Phase I / II Study abstract
Kelley RK, Sangro B, Harris W et al.
J Clin Oncol. 2021 Jul 22:JCO2003555.
doi:10.1200/JCO.20.03555
descarregue aqui o pdf

Socioeconomic Inequalities in the Incidence of Alcohol-Related Liver Disease: a Nationwide Danish Study
Askgaard G, Fleming K, Kraglund F, et al.
Hepatology. 2020;72(1):191A-192A.
doi:10.1016/j.lanepe.2021.10017
descarregue aqui o pdf

Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure
Campello E, Zanetto A, Bulato C, et al.
Liver Int. 2021;(May):1-12.
doi:10.1111/liv.1500
descarregue aqui o pdf

Outcomes After TIPS for Ascites and Variceal Bleeding in a Contemporary Era—An ALTA Group Study
Boike JR, Mazumder NR, Kolli KP et al.
Am J Gastroenterol. 2021 Jun 23.
doi: 10.14309/ajg.0000000000001357
link

Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study
Reig A, Álvarez-Navascués C, Vergara M et al.
Am J Gastroenterol. 2021 Jun 23.
doi: 10.14309/ajg.0000000000001343
link

Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review
Singal AK, Mathurin P.
JAMA. 2021;326(2):165–176.
doi:10.1001/jama.2021.7683
link

Genetic Disorders of Bile Acid Transport
Henkel AS.
Clin Liver Dis. 2021;0(0):1-6.
doi:10.1002/cld.1132
descarregue aqui o pdf

Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome
Dalekos GN, Azariadis K, Lygoura V, et al.
Liver Int. 2021;41(7):1592-1599.
doi:10.1111/LIV.14900
link

Comparison of fondaparinux and low molecular weight heparin in the treatment of portal vein thrombosis in cirrhosis
Senzolo M, Piano S, Shalaby S, et al.
Am J Med. 2021;0(0).
doi:10.1016/J.AMJMED.2021.05.013
link

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
Bömmel F, Berg T.
Hepatol Commun. 2021;0(0):1-17.
doi:10.1002/hep4.1708
DESCARREGUE AQUI O PDF

Early diarrhoea under sorafenib as a marker to consider the early migration to second ‐ line drugs
González ÁD, Sapena V, Zamparelli MS, et al.
United European Gastroenterol J. 2021;9(6):655-61.
doi:10.1002/ueg2.12111
DESCARREGUE AQUI O PDF

Estrogens in Polycystic Liver Disease: A Target for Future Therapies?
Aapkes SE, Bernts LHP, Barten TRM, et al.
Liver Int 2021.
doi:10.1111/liv.14986
DESCARREGUE AQUI O PDF

The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis
Arroyo V, Angeli P, Moreau R, et al.
J Hepatol. 2021;74(3):670-685.
doi:10.1016/j.jhep.2020.11.048
DESCARREGUE AQUI O PDF

Clinical management of patients with drug‐induced liver injury (DILI)
Björnsson ES.
United Eur Gastroenterol J. 2021;(March):1-6.
doi:10.1002/ueg2.12113
DESCARREGUE AQUI O PDF

End-stage liver disease: Management of hepatorenal syndrome
Mauro E, Garcia-Olveira L, Gadano A.
Liver Int. 2021;41(S1):119-127.
doi:10.1111/liv.14866
DESCARREGUE AQUI O PDF

Micronutrient deficiencies in patients with decompensated liver cirrhosis
Llibre-Nieto G, Lira A, Vergara M, et al.
Nutrients. 2021;13(4):1-14.
doi:10.3390/nu13041249
DESCARREGUE AQUI O PDF

EASL-CLIF criteria perform better than NACSELD to diagnose and prognosticate ACLF
Li F, Thuluvath PJ.
J Hepatol. Published online 2021.
doi:10.1016/j.jhep.2021.05.033
link

Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential
Brown SA, Izzy M, Watt KD.
Hepatology. 2021;73(5):2051-2062.
doi:10.1002/hep.31595
link

Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study
Arab JP, Díaz LA, Baeza N, et al.
European Association for the Study of the Liver; 2021.
doi:10.1016/j.jhep.2021.06.019
link

Direct Measurement of ATP7B Peptides Is Highly Effective in the Diagnosis of Wilson Disease
Collins CJ, Yi F, Dayuha R, et al.
Gastroenterology. 2021;160(7):2367-2382.e1.
doi:10.1053/j.gastro.2021.02.052
descarregue aqui o pdf

Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD
Oh S, Tsujimoto T, Kim B, et al.
JHEP Reports. 2021;3(3):100253.
doi:10.1016/j.jhepr.2021.100253
descarregue aqui o pdf

2020

Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025
Rodríguez-Tajes S, Pocurull A, Castillo J, et al.
J Hepatol. 2020;73(6):1360-1367
doi:10.1016/j.jhep.2020.07.018
link

A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.
Sven M. F, Pierre B, Manal F. A, et al.
Contemp Clin Trials 2020;98(August):106170.
doi:10.1016/j.cct.2020.106170
descarregue aqui o pdf

Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey’s discriminant function <32
Degré D, Stauber RE, Englebert G, et al.
J Hepatol. 2020;72(4):636-642.
doi:10.1016/j.jhep.2019.12.023
descarregue aqui o pdf

Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease
Wooddell CI, Blomenkamp K, Peterson RM, et al.
JCI Insight. 2020;5(12):1-19.
doi:10.1172/jci.insight.135348
descarregue aqui o pdf

APEF - ASSOCIAÇÃO PORTUGUESA PARA O ESTUDO DO FÍGADO
Rua Abranches Ferrão, nº 10 - 14º
1600-001 Lisboa Tel: 217995536 
Fax: 217995538
geral@apef.com.pt

Horário de funcionamento:
9.00 - 13.00, 14.00 - 18.00

Secretariado

Luis Maco
Diretor-Geral
luis.maco@apef.com.pt
Andreia Neto
andreia.neto@apef.com.pt
Teresa Jorge
teresa.jorge@apef.com.pt
Cândida Rodrigues

Tornar-se sócio

É favor enviar ao Presidente da APEF, até 3 meses da data da Assembleia Geral, a proposta devidamente preenchida, assinada por dois sócios titulares da APEF e acompanhada das notas curriculares (resumo cv), para: Geral@apef.com.pt ou para

APEF - ASSOCIAÇÃO PORTUGUESA PARA O ESTUDO DO FÍGADO, Rua Abranches Ferrão

Nº10 - 14º 1600-001 Lisboa.

Ficha de Inscrição